NGS Group (NGS) Q4 2024 earnings summary

Executive summary

• Net sales for Q4 2024 were 87 MSEK, down 15% year-over-year, with EBITA turning positive at 0.5 MSEK from -3.7 MSEK.

• Full-year net sales declined 26% to 350 MSEK, mainly due to lower demand in healthcare staffing and economic downturns.

• The sale of the Vikariepoolen business was completed, allowing focus on core operations.

• Cost control and increased demand in non-healthcare segments contributed to improved results despite lower sales.

Financial highlights

• Q4 EBITA was 0.5 MSEK (margin 0.5%), up from -3.7 MSEK (-3.6%) year-over-year.

• Q4 net result was -0.2 MSEK, EPS -0.01 SEK.

• Full-year EBITA was -22.6 MSEK (-6.4% margin), and EBIT -72.6 MSEK (-20.7% margin).

• Full-year net result was -71.9 MSEK, EPS -3.68 SEK.

• Adjusted full-year result (excluding goodwill write-downs and restructuring) was -15.1 MSEK.

• Q4 operating cash flow was 5.0 MSEK; full-year operating cash flow was -20.3 MSEK.

• No dividend proposed for the year.

Outlook and guidance

• Management expects gradual improvement in non-healthcare segments as the economy recovers.

• Continued focus on sales, marketing, and cost control to support profitability.